New data on adjuvant pembrolizumab after kidney cancer surgery presented by Dana-Farber's Toni Choueiri, MD, at #ASCO22. KEYNOTE-564 shows prolonged distant metastasis-free survival and clinically relevant time to subsequent anticancer therapy and 2nd disease progression. Video published June 4, 2022